Trial Profile
Prospective, double-blind, randomized non-inferiority study of darbepoetin alfa (DA) for treatment of anemia in patients with chronic kidney disease, not on dialysis (CKD-ND)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2015
Price :
$35
*
At a glance
- Drugs Darbepoetin alfa (Primary)
- Indications Anaemia
- Focus Adverse reactions; Therapeutic Use
- 03 Nov 2015 New trial record